on SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma Reports Strong Growth and Record Margins for FY 2024
SCHOTT Pharma AG & Co. KGaA achieved robust financial results for the fiscal year 2024. Revenues grew by 12% at constant currencies, reaching EUR 957 million, with EBITDA rising to EUR 258 million. The EBITDA margin improved to 26.9%, attributed to high demand for the company's high-value solutions (HVS), which constituted 55% of annual revenue.
The Drug Delivery Systems (DDS) segment was a key driver, achieving EUR 439 million in revenue, up 28% year-on-year. The Drug Containment Solutions (DCS) segment also saw positive growth at constant currencies. SCHOTT Pharma's innovations, such as the improved SCHOTT TOPPAC® Nest 160 for syringes, supported growth by enhancing sustainability and efficiency.
Looking ahead, SCHOTT Pharma anticipates continued strong revenues and earnings growth, driven by product innovation and capacity expansion.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SCHOTT Pharma AG & Co. KGaA news